Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Effectiveness of Covaxin against the Omicron variant is currently being studied
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
The interim data combines three mRNAs into one therapy injected directly into the tumour
The division is expected to grow to over a 100-member strong team by 2022
Subscribe To Our Newsletter & Stay Updated
